Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive

Consumers who buy brand-name prescription drugs without an available generic or biosimilar at the prices available through the new TrumpRx website are about as likely to pay more as pay less for those drugs relative to the publicly listed prices available in other comparatively wealthy countries, a new KFF analysis finds.

The Trump administration has promoted the TrumpRx website as a way for consumers to get the lowest prices for prescription medications in the world, drawing on voluntary pricing agreements with drug manufacturers aimed at securing “Most Favored Nation” prices for American consumers. For many brand-name drugs listed on the website, TrumpRx directs consumers to manufacturers’ discount coupons to get the drugs at a pharmacy without using insurance.

The analysis compares the prices of 32 brand-name drugs listed on the TrumpRx website with those in other countries. Key findings include:

• For 17 of the 32 drugs, the TrumpRx price is lower than the average price in comparable countries. This includes five drugs for which the TrumpRx price is lower than the prices available in any of the other countries. Eight drugs have a price that is $100 less than the average in other countries.
• For the other 15 drugs, the TrumpRx price is higher than the average price in comparable countries. This includes 13 drugs for which the TrumpRx price is higher than prices available in any of the other countries.
• There are wide variations in the price differences between TrumpRx and other countries. For nine of the drugs, the prices on TrumpRx are at least double the average across other countries. This includes Enbrel, a drug used to treat rheumatoid arthritis; the TrumpRx price is $2,725 higher than the average across other countries ($3,354 versus $641).

This analysis compares the TrumpRx drug prices with available prices in Australia, Austria, Belgium, Canada, France, Germany, Japan, the Netherlands, Sweden, Switzerland, and the United Kingdom for the brand-name drugs listed on the TrumpRx site (as of August 25, 2026) that do not have generics or biosimilars available in the U.S. and that had publicly available prices in at least one of the other nations. It does not compare the prices available on TrumpRx now to the prices that may have been available to consumers in the U.S. prior to its launch.

There is no one source of data for drug prices in other countries. In many cases, the publicly listed prices used in the analysis represent the price paid by the government’s national health system, or similar entity, and not necessarily what a consumer living in the country and covered by its health system would pay.

The analysis also examines some of the factors that contribute to differences in prices across countries and through TrumpRx, including the role of government in setting drug prices. The analysis is available through the Peterson-KFF Health System Tracker, an online hub monitoring how well the U.S. health system is operating through cost and quality measures.